1 |
Fampyra 10mg prolonged release tablets |
- |
- |
- |
- |
013 [1] 13 💬 |
2 |
Mezavant gastro-resistant, prolonged release tablets |
- |
- |
- |
- |
097 [1] 97 💬 |
3 |
Mezavant xl 1200 mg gastro-resistant prolonged release tablets |
- |
- |
- |
- |
097 [1] 97 💬 |
4 |
Mezavant xl 1200 mg gastro-resistant, prolonged release tablets |
- |
- |
- |
- |
097 [1] 97 💬 |
5 |
Mezavant xl 1200 mg gastro-resistant, prolonged release tablets. |
- |
- |
- |
- |
097 [1] 97 💬 |
6 |
Mezavant xl 1200mg gastro-resistant, prolonged release tablets |
- |
- |
- |
- |
097 [1] 97 💬 |
7 |
Mezavant xl gastro-resistant, prolonged release tablets |
- |
- |
- |
- |
097 [1] 97 💬 |
8 |
Oxycodone naloxone prolonged release tablets |
Naloxone |
[5] D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 [1] 226 💬 |
9 |
Oxycodone/naloxone prolonged release tablets |
Naloxone |
[5] D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 [1] 6 💬 |
10 |
Oxycodone/naloxone prolonged release tablets 10 mg /5 mg |
Naloxone |
[5] D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 [1] 6 💬 |
11 |
Oxycodone/naloxone prolonged release tablets 10/5 mg |
Naloxone |
[5] D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 [1] 226 💬 |
12 |
Oxycodone/naloxone prolonged release tablets 20 mg /10 mg |
Naloxone |
[5] D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 [1] 6 💬 |
13 |
Oxycodone/naloxone prolonged release tablets 20/10 mg |
Naloxone |
[5] D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 [1] 226 💬 |
14 |
Oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg |
Naloxone |
[5] D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 [1] 6 💬 |
15 |
Oxycodone/naloxone prolonged release tablets 5/2.5 mg |
Naloxone |
[5] D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 [1] 226 💬 |
16 |
Prolonged release tablet |
- |
- |
- |
- |
006 [1] 6 💬 |
17 |
Tofacitinib (xeljanz®) 11mg prolonged release tablet |
Tofacitinib |
[1] D09970 D09970 💬 |
JAK1 [4] JAK1, JAK2, JAK3, TYK2 💬 |
AGE-RAGE signaling pathway in diabetic complications [35] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
046 [1] 46 💬 |